|By Marketwired .||
|November 6, 2012 02:03 AM EST||
BASEL, SWITZERLAND -- (Marketwire) -- 11/06/12 -- Basilea Pharmaceutica AG / Basilea's novel oncology drug candidate BAL101553: data presented at international conference demonstrate dual mode of action. Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that new research data on its innovative anti-cancer drug BAL101553 are being presented at the 24(th) Symposium on "Molecular Targets and Cancer Therapeutics" taking place in Dublin, Ireland, from November 6 to 9, 2012, hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the U.S. National Cancer Institute (NCI) and the American Association for Cancer Research (AACR).
BAL101553, a highly soluble prodrug of Basilea's BAL27862, is a novel small molecule agent targeting microtubules, the intracellular structural network essential for cell division. BAL27862 has demonstrated broad anti-cancer activity in preclinical models of human cancer resistant to conventional microtubule-targeting drugs such as taxanes or vinca alkaloids. BAL101553 has potential for both intravenous and oral administration. The injectable form is currently being tested in a phase I study in patients with advanced solid tumors.
BAL101553 has a dual mechanism of action (poster/abstract #421) with direct activity against drug-resistant cancer cells and a pronounced effect on eliminating tumor blood supply. In animal models, short-term treatment of tumors led to a dramatic reduction in tumor cell growth and viability, associated with almost complete eradication of functional tumor blood vessels. Importantly, blood vessel function in normal tissue was not affected. Vascular disruption activity was also shown in an in vitro model that mimics capillary formation.
Further data supporting the unique anti-cancer profile and mode of action of this novel agent were generated in collaboration with the group of Diane Braguer of the Aix-Marseille University, France. Details of distinct effects on microtubule biology are presented (poster/abstract #422). These show that BAL27862 blocks tumor cell division by altering microtubule dynamics in a unique way as compared to conventional microtubule-targeting agents.
Dr. Laurenz Kellenberger, Basilea's Chief Scientific Officer, commented: "Resistance against established drugs is a major challenge in cancer therapy and necessitates the development of new oncology drugs with novel mechanisms of action to overcome such resistance. The dual mode of action of BAL101553, attacking tumor cells that are resistant to other agents as well as disrupting blood vessels of the tumor underlines its promising profile as a potential new agent for the treatment of refractory human cancers."
+--------------------------------------------------------------+ |Posters on BAL101553/BAL27862 | |to be presented in poster session "Tubulin-Interacting Agents"| |on November 8, 2012 | | | |Dual mechanism of action of the novel microtubule-targeting | |drug BAL27862 (active moiety of the prodrug BAL101553): | |targeting tumor and vascular cells - F. Bachmann, H.A. Lane; | |poster #421 | | | |Antitumor activity of BAL27862 (active moiety of the prodrug | |BAL101553) is associated with the generation of short | |non-centrosomal microtubules - A. Rovini, S. Honoré, N. | |McKay, F. Bachmann, H.A. Lane, D. Braguer; poster #422 | +--------------------------------------------------------------+
For further information please visit www.ecco-org.eu/ENA.
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through the fully integrated research and development operations of its Swiss subsidiary Basilea Pharmaceutica International Ltd. ("Basilea") the company focuses on innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and non-response to current treatment options.
This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
This press release can be downloaded from www.basilea.com.
Press release (PDF): http://hugin.info/134390/R/1655161/534808.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Basilea Pharmaceutica AG via Thomson Reuters ONE
Data-intensive companies that strive to gain insights from data using Big Data analytics tools can gain tremendous competitive advantage by deploying data-centric storage. Organizations generate large volumes of data, the vast majority of which is unstructured. As the volume and velocity of this unstructured data increases, the costs, risks and usability challenges associated with managing the unstructured data (regardless of file type, size or device) increases simultaneously, including end-to-...
May. 24, 2015 10:30 AM EDT Reads: 4,076
If cloud computing benefits are so clear, why have so few enterprises migrated their mission-critical apps? The answer is often inertia and FUD. No one ever got fired for not moving to the cloud - not yet. In his session at 15th Cloud Expo, Michael Hoch, SVP, Cloud Advisory Service at Virtustream, discussed the six key steps to justify and execute your MCA cloud migration.
May. 24, 2015 10:30 AM EDT Reads: 2,712
WebRTC defines no default signaling protocol, causing fragmentation between WebRTC silos. SIP and XMPP provide possibilities, but come with considerable complexity and are not designed for use in a web environment. In his session at @ThingsExpo, Matthew Hodgson, technical co-founder of the Matrix.org, discussed how Matrix is a new non-profit Open Source Project that defines both a new HTTP-based standard for VoIP & IM signaling and provides reference implementations.
May. 24, 2015 10:30 AM EDT Reads: 5,071
SYS-CON Events announced today that the "First Containers & Microservices Conference" will take place June 9-11, 2015, at the Javits Center in New York City. The “Second Containers & Microservices Conference” will take place November 3-5, 2015, at Santa Clara Convention Center, Santa Clara, CA. Containers and microservices have become topics of intense interest throughout the cloud developer and enterprise IT communities.
May. 24, 2015 10:00 AM EDT Reads: 1,792
Buzzword alert: Microservices and IoT at a DevOps conference? What could possibly go wrong? In this Power Panel at DevOps Summit, moderated by Jason Bloomberg, the leading expert on architecting agility for the enterprise and president of Intellyx, panelists will peel away the buzz and discuss the important architectural principles behind implementing IoT solutions for the enterprise. As remote IoT devices and sensors become increasingly intelligent, they become part of our distributed cloud en...
May. 24, 2015 10:00 AM EDT Reads: 1,664
Can the spatial component of your Big Data be harnessed and visualized, adding another dimension of power and analytics to your data? In his session at Big Data Expo®, John Meza, Product Engineer and Performance Engineering Team Lead at Esri, discussed the spatial queries that can be used within the Hadoop ecosystem and their integration with GeoSpatial applications. The GIS Tools for Hadoop project was also discussed and its implementation to discover location-based patterns and relationships...
May. 24, 2015 09:30 AM EDT Reads: 3,413
“We are strong believers in the DevOps movement and our staff has been doing DevOps for large enterprise environments for a number of years. The solution that we build is intended to allow DevOps teams to do security at the speed of DevOps," explained Justin Lundy, Founder & CTO of Evident.io, in this SYS-CON.tv interview at DevOps Summit, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
May. 24, 2015 09:30 AM EDT Reads: 4,505
Almost everyone sees the potential of Internet of Things but how can businesses truly unlock that potential. The key will be in the ability to discover business insight in the midst of an ocean of Big Data generated from billions of embedded devices via Systems of Discover. Businesses will also need to ensure that they can sustain that insight by leveraging the cloud for global reach, scale and elasticity.
May. 24, 2015 09:30 AM EDT Reads: 6,398
Docker is becoming very popular--we are seeing every major private and public cloud vendor racing to adopt it. It promises portability and interoperability, and is quickly becoming the currency of the Cloud. In his session at DevOps Summit, Bart Copeland, CEO of ActiveState, discussed why Docker is so important to the future of the cloud, but will also take a step back and show that Docker is actually only one piece of the puzzle. Copeland will outline the bigger picture of where Docker fits a...
May. 24, 2015 09:00 AM EDT Reads: 5,991
The 4th International Internet of @ThingsExpo, co-located with the 17th International Cloud Expo - to be held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA - announces that its Call for Papers is open. The Internet of Things (IoT) is the biggest idea since the creation of the Worldwide Web more than 20 years ago.
May. 24, 2015 09:00 AM EDT Reads: 1,330
SYS-CON Media named Andi Mann editor of DevOps Journal. DevOps Journal is focused on this critical enterprise IT topic in the world of cloud computing. DevOps Journal brings valuable information to DevOps professionals who are transforming the way enterprise IT is done. Andi Mann, Vice President, Strategic Solutions, at CA Technologies, is an accomplished digital business executive with extensive global expertise as a strategist, technologist, innovator, marketer, communicator, and thought lea...
May. 24, 2015 09:00 AM EDT Reads: 1,089
Announced separately, New Relic is joining the Cloud Foundry Foundation to continue the support of customers and partners investing in this leading PaaS. As a member, New Relic is contributing the New Relic tile, service broker and build pack with the goal of easing the development of applications on Cloud Foundry and enabling the success of these applications without dedicated monitoring infrastructure. Supporting Quotes "The proliferation of microservices and new technologies like Docker ha...
May. 24, 2015 09:00 AM EDT Reads: 1,592
Even though it’s now Microservices Journal, long-time fans of SOA World Magazine can take comfort in the fact that the URL – soa.sys-con.com – remains unchanged. And that’s no mistake, as microservices are really nothing more than a new and improved take on the Service-Oriented Architecture (SOA) best practices we struggled to hammer out over the last decade. Skeptics, however, might say that this change is nothing more than an exercise in buzzword-hopping. SOA is passé, and now that people are ...
May. 24, 2015 09:00 AM EDT Reads: 3,295
You often hear the two titles of "DevOps" and "Immutable Infrastructure" used independently. In his session at DevOps Summit, John Willis, Technical Evangelist for Docker, will cover the union between the two topics and why this is important. He will cover an overview of Immutable Infrastructure then show how an Immutable Continuous Delivery pipeline can be applied as a best practice for "DevOps." He will end the session with some interesting case study examples.
May. 24, 2015 09:00 AM EDT Reads: 1,495
There is little doubt that Big Data solutions will have an increasing role in the Enterprise IT mainstream over time. 8th International Big Data Expo, co-located with 17th International Cloud Expo - to be held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA - has announced its Call for Papers is open. As advanced data storage, access and analytics technologies aimed at handling high-volume and/or fast moving data all move center stage, aided by the cloud computing bo...
May. 24, 2015 08:45 AM EDT Reads: 1,244